140646-13-5

Basic information

• Product Name: TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE
• Synonyms: TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE;2-Piperidinecarboxylicacid,1,1-dimethylethylester,(2R)-;2-Methyl-2-propanyl (2R)-2-piperidinecarboxylate
• CAS NO: 140646-13-5
• Molecular Formula: C₁₀H₁₉NO₂
• Molecular Weight: 185.265
• Mol File: 140646-13-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE(140646-13-5)
• EPA Substance Registry System: TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE(140646-13-5)

Safety Data

• Hazardous Substances Data: 140646-13-5(Hazardous Substances Data)

Usage

Description

TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE is a chemical compound with the molecular formula C11H21NO2. It is an ester derivative of (R)-2-piperidinecarboxylic acid, which serves as a key intermediate in the synthesis of pharmaceuticals and agrochemicals. TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE is widely recognized for its role as a building block in the production of various drugs and active pharmaceutical ingredients, especially in the development of chiral compounds. Its chiral nature is crucial in medicinal chemistry and drug discovery, as it can significantly influence the biological activity and pharmacokinetics of the resulting molecules. Furthermore, TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE has garnered interest for its potential insecticidal and acaricidal properties, making it a subject of study in agrochemical research.

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE is used as a key intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its chiral nature is essential in the development of chiral compounds, which can impact the biological activity and pharmacokinetics of the resulting molecules.
Used in Agrochemical Research:
TERT-BUTYL (R)-2-PIPERIDINECARBOXYLATE is used as a subject of study for its potential insecticidal and acaricidal properties. Its investigation in this field aims to explore its effectiveness in controlling pests and parasites, contributing to the development of new agrochemical products.

Upstream product

• 540-88-5 acetic acid tert-butyl ester 
• 1723-00-8 (R)-(+)-pipecolic acid 
• 115-11-7 isobutene 
• 1416352-41-4 (R)-tert-butyl 5-(1,3-dioxolan-2-yl)-2-(diphenylmethyleneamino)pentanoate 

Relevant articles and documents

Challenges in the Development of a Thiol-Based Broad-Spectrum Inhibitor for Metallo-β-Lactamases

Pathogens, expressing metallo-β-lactamases (MBLs), become resistant against most β-lactam antibiotics. Besides the dragging search for new antibiotics, development of MBL inhibitors would be an alternative weapon against resistant bacterial pathogens. Inhibition of resistance enzymes could restore the antibacterial activity of β-lactams. Various approaches to MBL inhibitors are described; among others, the promising motif of a zinc coordinating thiol moiety is very popular. Nevertheless, since the first report of a thiol-based MBL inhibitor (thiomandelic acid) in 2001, no steps in development of thiol based MBL inhibitors were reported that go beyond clinical isolate testing. In this study, we report on the synthesis and biochemical characterization of thiol-based MBL inhibitors and highlight the challenges behind the development of thiol-based compounds, which exhibit good in vitro activity toward a broad spectrum of MBLs, selectivity against human off-targets, and reasonable activity against clinical isolates.

Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines

1-Isoquinolinylguanidines were previously disclosed as potent and selective inhibitors of urokinase-type plasminogen activator (uPA). Further investigation of this template has revealed that incorporation of a 7-sulfonamide group furnishes a new series of potent and highly selective uPA inhibitors. Potency and selectivity can be achieved with sulfonamides derived from a variety of amines and is further enhanced by the incorporation of sulfonamides derived from amino acids. The binding mode of these 1-isoquinolinylguanidines has been investigated by X-ray cocrystallization studies. uPA inhibitor 26 was selected for further evaluation based on its excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin). In vitro, compound 26 is able to inhibit exogenous uPA in human chronic wound fluid (IC50 = 0.89 μM). In vivo, in a porcine acute excisional wound model, following topical delivery, compound 26 is able to penetrate into pig wounds and inhibit exogenous uPA activity with no adverse effect on wound healing parameters. On the basis of this profile, compound 26 (UK-371,804) was selected as a candidate for further preclinical evaluation for the treatment of chronic dermal ulcers.

Composition for the treatment of damaged tissue

A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.